Literature DB >> 30150446

Pathological Complete Response by S-1 Chemotherapy in Advanced Gastric Cancer.

Tsutomu Namikawa1, Nobuko Ishida2, Sachi Tsuda2, Kazune Fujisawa2, Eri Munekage2, Jun Iwabu2, Masaya Munekage2, Sunao Uemura2, Shigehiro Tsujii2, Hiromichi Maeda3, Hiroyuki Kitagawa2, Michiya Kobayashi3,4, Kazuhiro Hanazaki2.   

Abstract

A pathological complete response (pCR) to treatment for gastric cancer is a rare event, even when powerful treatment regimens are used. Herein, a case of 61-year-old male referred to our hospital with advanced gastric cancer who achieved a pCR following chemotherapy using S-1, and subsequently underwent total gastrectomy is reported. His initial esophagogastroduodenoscopy (EGD) revealed an irregular, nodular, ulcerated lesion in the upper third of the stomach that was analyzed by biopsy to be a moderately differentiated adenocarcinoma. Abdominal contrast-enhanced computed tomography (CT) showed gastric wall thickening and lymph node swelling in the perigastric area. The patient was clinically diagnosed with cT3N1M0, stage IIB advanced gastric cancer. The patient decided against curative surgery due to his work circumstances and was started on S-1 (80 mg/m2) chemotherapy administered orally twice a day for 4 weeks, followed by 2 weeks of no chemotherapy. After four such courses of systemic S-1 chemotherapy, EGD showed a small, reddened lesion with aggregated, whitish lines. The gastric wall thickening and lymphadenopathy in the perigastric area were also reduced remarkably. The patient subsequently agreed to surgery, undergoing total gastrectomy with D2 lymphadenectomy. Gross examination of the surgically resected specimen showed a slightly erythrogenic, flat lesion measuring 1.5×1.0 cm. Pathological examination of the resected specimen and harvested lymph nodes detected no malignant cells. The postoperative course was uneventful. The patient has continued to receive S-1 chemotherapy, with no evidence of recurrence at 4 months post-surgery. To the best of our knowledge, this is only the second case of a gastric cancer patient achieving a pCR by S-1 monotherapy reported in the English literature and indicates the potential adoption of curative resection after S-1 chemotherapy as a treatment strategy for advanced gastric cancer. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Gastric cancer; S-1; chemotherapy; complete response; preoperative therapy

Mesh:

Substances:

Year:  2018        PMID: 30150446      PMCID: PMC6199615          DOI: 10.21873/invivo.11366

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  19 in total

1.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

Review 2.  Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy.

Authors:  Takaki Yoshikawa; Yasushi Rino; Norio Yukawa; Takashi Oshima; Akira Tsuburaya; Munetaka Masuda
Journal:  Surg Today       Date:  2013-03-19       Impact factor: 2.549

3.  Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial.

Authors:  Takaki Yoshikawa; Kazuaki Tanabe; Kazuhiro Nishikawa; Yuichi Ito; Takanori Matsui; Yutaka Kimura; Naoki Hirabayashi; Shoki Mikata; Makoto Iwahashi; Ryoji Fukushima; Nobuhiro Takiguchi; Isao Miyashiro; Satoshi Morita; Yumi Miyashita; Aakira Tsuburaya; Junichi Sakamoto
Journal:  Ann Surg Oncol       Date:  2013-07-10       Impact factor: 5.344

4.  First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.

Authors:  Akitaka Makiyama; Kenji Kunieda; Masaaki Noguchi; Takeshi Kajiwara; Takao Tamura; Koji Takeda; Junko Sugiyama; Keiko Minashi; Toshikazu Moriwaki; Naotoshi Sugimoto; Michitaka Nagase; Yuji Negoro; Takashi Tsuda; Hideki Shimodaira; Naohiro Okano; Akihito Tsuji; Daisuke Sakai; Kazuhiro Yanagihara; Shinya Ueda; Shingo Tamura; Satoshi Otsu; Takuya Honda; Yuzo Matsushita; Tatsuya Okuno; Tomomi Kashiwada; Akira Nozaki; Masahide Ebi; Hiroyuki Okuda; Mototsugu Shimokawa; Shuichi Hironaka; Ichinosuke Hyodo; Eishi Baba; Narikazu Boku; Kei Muro; Taito Esaki
Journal:  Gastric Cancer       Date:  2018-01-20       Impact factor: 7.370

5.  Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy.

Authors:  Shusuke Mori; Hirofumi Kishimoto; Katsunori Tauchi; Kayoko Higuchi
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

6.  Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1).

Authors:  T Namikawa; I Fukudome; M Ogawa; E Munekage; M Munekage; M Shiga; H Maeda; H Kitagawa; M Kobayashi; K Hanazaki
Journal:  Eur J Surg Oncol       Date:  2015-04-03       Impact factor: 4.424

7.  Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.

Authors:  Tsutomu Namikawa; Eri Munekage; Hiromichi Maeda; Hiroyuki Kitagawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Anticancer Res       Date:  2014-12       Impact factor: 2.480

8.  Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Jaffer A Ajani; Thomas A D'Amico; Khaldoun Almhanna; David J Bentrem; Joseph Chao; Prajnan Das; Crystal S Denlinger; Paul Fanta; Farhood Farjah; Charles S Fuchs; Hans Gerdes; Michael Gibson; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kimberly L Johung; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; Stephen Leong; Catherine Linn; A Craig Lockhart; Quan P Ly; Mary F Mulcahy; Mark B Orringer; Kyle A Perry; George A Poultsides; Walter J Scott; Vivian E Strong; Mary Kay Washington; Benny Weksler; Christopher G Willett; Cameron D Wright; Debra Zelman; Nicole McMillian; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2016-10       Impact factor: 11.908

9.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

10.  Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.

Authors:  Yi Liu; Ke-Cheng Zhang; Xiao-Hui Huang; Hong-Qing Xi; Yun-He Gao; Wen-Quan Liang; Xin-Xin Wang; Lin Chen
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

View more
  1 in total

1.  Pathological complete response in a patient with locally advanced pancreatic adenocarcinoma treated with neoadjuvant gemcitabine and S-1: a case report and literature review.

Authors:  Surong Hua; Junyi Gao; Qiang Xu; Xiafei Hong; Wenming Wu
Journal:  Gland Surg       Date:  2022-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.